サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1514171

ナルコレプシー治療薬の世界市場

Narcolepsy Therapeutics

出版日
ページ情報
英文 363 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
ナルコレプシー治療薬の世界市場
出版日: 2024年07月17日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 363 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ナルコレプシー治療薬の世界市場は2030年までに36億米ドルに達する見込み

2023年に22億米ドルと推定されるナルコレプシー治療薬の世界市場は、2030年には36億米ドルに達し、分析期間2023-2030年のCAGRは7.2%で成長すると予測されます。本レポートで分析したセグメントの1つであるカタプレキシーを伴うナルコレプシー治療薬は、CAGR 6.9%を記録し、分析期間終了までに19億米ドルに達すると予測されます。カタプレキシーを伴わないナルコレプシー治療薬セグメントの成長率は、分析期間中CAGR 8.1%と推定されます。

米国市場は5億9,690万米ドル、中国はCAGR11.5％で成長予測

米国のナルコレプシー治療薬市場は、2023年に5億9,690万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2023-2030年のCAGR11.5%を牽引し、2030年までに8億3,380万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.8%と7.4%と予測されています。欧州では、ドイツがCAGR 4.1%で成長すると予測されています。

ナルコレプシー治療薬-主要動向と促進要因

ナルコレプシーは、日中の過度の眠気、カタプレキシー、睡眠麻痺、幻覚などを特徴とする慢性的な神経疾患で、この疾患に苦しむ人々のニーズに対応する、医学研究と治療の重要な分野です。ナルコレプシー治療の第一の目標は、症状を管理し、患者の生活の質を改善することです。現在の治療選択肢には、刺激薬、オキシベートナトリウム、選択的セロトニン・ノルエピネフリン再取り込み阻害薬（SNRI）などの薬剤があります。モダフィニルやアルモダフィニルのような覚醒剤は、覚醒を促進することによって日中の過度の眠気に対処するのに役立ち、オキシベートナトリウムはカタプレキシーを軽減し、夜間の睡眠を改善するのに有効です。さらに、SNRIやその他の抗うつ薬も、カタプレキシーやその他の関連症状の管理に利用されます。これらの薬剤はしばしば併用され、ナルコレプシーの多様な症状を反映した、オーダーメイドの治療アプローチが提供されます。

ナルコレプシー治療薬における最近の進歩は、患者の予後を著しく改善し、治療の展望を広げています。新規オレキシン受容体作動薬のような革新的な薬剤は、治療開発の最前線にあります。オレキシンは覚醒を調節する神経ペプチドであり、多くのナルコレプシー患者、特に1型ナルコレプシー患者では欠損しています。オレキシン受容体作動薬は、オレキシンの作用を模倣することにより、過度の眠気とカタプレキシーの根本原因に対処することを目的としています。さらに、遺伝子調査とバイオマーカー同定の進歩により、より正確で個別化された治療戦略への道が開かれつつあります。これらの開発は、既存の治療法の有効性を高めるだけでなく、新たな治療ターゲットの発見にも貢献しています。モバイルアプリやウェアラブルデバイスなどのデジタルヘルス技術の統合も、ナルコレプシーの管理において重要な役割を果たしています。これらの技術は、睡眠パターンや服薬アドヒアランスの継続的なモニタリングを可能にし、治療計画の最適化に利用できる貴重なデータを提供します。

ナルコレプシー治療薬市場の成長は、いくつかの要因によってもたらされます。ナルコレプシーに対する認識と診断の高まりにより、効果的な治療に対する需要が高まっています。医学研究、特にナルコレプシーの遺伝的・分子的基盤の解明における研究開発が、革新的な治療法の開発を後押ししています。ナルコレプシーの有病率の上昇は、ヘルスケアインフラの改善と相まって、診断・治療サービスへのアクセスを向上させています。さらに、個別化医療が受け入れられつつあることが、遺伝子やバイオマーカー情報に基づき個々の患者のプロファイルに合わせた標的療法の採用を後押ししています。製薬会社は、より効果的な新規ナルコレプシー治療薬を上市するため、研究開発に多額の投資を行っています。また、新規ナルコレプシー治療薬に対する規制当局の支援や希少疾病用医薬品の指定も、新規治療薬の開発を後押ししています。さらに、患者支援団体は、認知度の向上、研究資金の提供、臨床試験の支援において重要な役割を果たしており、市場の成長に寄与しています。これらの要因が相まって、ナルコレプシー治療薬市場のダイナミックで進化的な性質が強調され、今後数年間で患者にとってより良い結果がもたらされることが期待されます。

調査対象企業の例（全14件）

  • Arena Pharmaceuticals, Inc.
  • BioProjet Pharma
  • Graymark Healthcare, Inc.
  • Jazz Pharmaceuticals PLC
  • Ligand Pharmaceuticals, Inc.
  • Shionogi, Inc.
  • Shire PLC
  • Teva Pharmaceutical Industries Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP-6594

Global Narcolepsy Therapeutics Market to Reach US$3.6 Billion by 2030

The global market for Narcolepsy Therapeutics estimated at US$2.2 Billion in the year 2023, is expected to reach US$3.6 Billion by 2030, growing at a CAGR of 7.2% over the analysis period 2023-2030. Narcolepsy with Cataplexy Therapeutics, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$1.9 Billion by the end of the analysis period. Growth in the Narcolepsy without Cataplexy Therapeutics segment is estimated at 8.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$596.9 Million While China is Forecast to Grow at 11.5% CAGR

The Narcolepsy Therapeutics market in the U.S. is estimated at US$596.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$833.8 Million by the year 2030 trailing a CAGR of 11.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 7.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Narcolepsy Therapeutics - Key Trends and Drivers

Narcolepsy therapeutics represent a critical area of medical research and treatment, addressing the needs of individuals afflicted by this chronic neurological disorder characterized by excessive daytime sleepiness, cataplexy, sleep paralysis, and hallucinations. The primary goal of narcolepsy treatment is to manage symptoms and improve patients' quality of life. Current therapeutic options include medications such as stimulants, sodium oxybate, and selective serotonin and norepinephrine reuptake inhibitors (SNRIs). Stimulants like modafinil and armodafinil help combat excessive daytime sleepiness by promoting wakefulness, while sodium oxybate is effective in reducing cataplexy and improving nighttime sleep. Additionally, SNRIs and other antidepressants are utilized to manage cataplexy and other associated symptoms. These medications, often used in combination, provide a tailored approach to treatment, reflecting the diverse manifestations of narcolepsy.

Recent advancements in narcolepsy therapeutics are significantly enhancing patient outcomes and expanding the treatment landscape. Innovations such as novel orexin receptor agonists are at the forefront of therapeutic development. Orexin, a neuropeptide that regulates wakefulness, is deficient in many individuals with narcolepsy, particularly those with type 1 narcolepsy. Orexin receptor agonists aim to mimic the action of orexin, thereby addressing the root cause of excessive sleepiness and cataplexy. Furthermore, advancements in genetic research and biomarker identification are paving the way for more precise and personalized treatment strategies. These developments not only enhance the efficacy of existing treatments but also contribute to the discovery of new therapeutic targets. The integration of digital health technologies, including mobile apps and wearable devices, is also playing a crucial role in managing narcolepsy. These technologies enable continuous monitoring of sleep patterns and medication adherence, providing valuable data that can be used to optimize treatment plans.

The growth in the narcolepsy therapeutics market is driven by several factors. Increasing awareness and diagnosis of narcolepsy are leading to a higher demand for effective treatments. Advancements in medical research, particularly in understanding the genetic and molecular basis of the disorder, are driving the development of innovative therapies. The rising prevalence of narcolepsy, coupled with improved healthcare infrastructure, is facilitating better access to diagnostic and therapeutic services. Additionally, the growing acceptance of personalized medicine is propelling the adoption of targeted therapies, which are tailored to individual patient profiles based on genetic and biomarker information. Pharmaceutical companies are investing heavily in research and development to bring new and more effective narcolepsy treatments to market. Regulatory support and the designation of orphan drug status for new narcolepsy medications are also incentivizing the development of novel therapeutics. Furthermore, patient advocacy groups are playing a crucial role in raising awareness, funding research, and supporting clinical trials, thereby contributing to market growth. These factors collectively underscore the dynamic and evolving nature of the narcolepsy therapeutics market, promising better outcomes for patients in the years to come.

Select Competitors (Total 14 Featured) -

  • Arena Pharmaceuticals, Inc.
  • BioProjet Pharma
  • Graymark Healthcare, Inc.
  • Jazz Pharmaceuticals PLC
  • Ligand Pharmaceuticals, Inc.
  • Shionogi, Inc.
  • Shire PLC
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Narcolepsy Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Awareness and Diagnosis of Narcolepsy Spurs Demand for Therapeutics
    • Advances in Genetic Research Throw the Spotlight on Personalized Narcolepsy Treatments
    • Innovations in Orexin Receptor Agonists Propel Growth in Narcolepsy Therapeutics Market
    • Integration of Digital Health Technologies Expands Addressable Market Opportunity
    • Improved Healthcare Infrastructure Strengthens Business Case for Narcolepsy Treatments
    • Pharmaceutical Investments in R&D Accelerate Development of Advanced Narcolepsy Drugs
    • Patient Advocacy Groups Drive Market Growth and Research Funding
    • Increasing Prevalence of Narcolepsy Generates Demand for Effective Treatment Options
    • Rising Acceptance of Personalized Medicine Throws the Spotlight on Targeted Therapies
    • Enhanced Understanding of Molecular Mechanisms Improves Treatment Efficacy
    • Early Diagnosis Techniques Strengthen Business Case for Comprehensive Treatment Plans
    • Expansion of Clinical Trials Accelerates New Therapeutic Approvals
    • Advances in Drug Delivery Systems Propel Growth in Narcolepsy Therapeutics Market
    • Global Initiatives and Funding for Sleep Disorders Research Drives Market Expansion
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Narcolepsy Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Narcolepsy Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Narcolepsy Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Narcolepsy with Cataplexy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Narcolepsy with Cataplexy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Narcolepsy with Cataplexy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Narcolepsy without Cataplexy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Narcolepsy without Cataplexy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Narcolepsy without Cataplexy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Secondary Narcolepsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Secondary Narcolepsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Secondary Narcolepsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Sodium Oxybate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Sodium Oxybate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Sodium Oxybate by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Central Nervous System Stimulants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Central Nervous System Stimulants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Central Nervous System Stimulants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Selective Serotonin Reuptake Inhibitor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Selective Serotonin Reuptake Inhibitor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Selective Serotonin Reuptake Inhibitor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Tricyclic Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Tricyclic Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Tricyclic Antidepressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • JAPAN
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • CHINA
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: China 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • EUROPE
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Narcolepsy Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Narcolepsy Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • FRANCE
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: France 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • GERMANY
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Narcolepsy Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Narcolepsy Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • INDIA
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: India 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: India 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Narcolepsy Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Narcolepsy Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Narcolepsy Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Narcolepsy Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • AFRICA
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030

IV. COMPETITION